CRISPR Therapeutics ($CRSP) has endured a tough year since gaining several important regulatory approvals for its ...

CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...

The company finished September with $1.9 billion in cash. A big cash pile gives CRISPR Therapeutics a long runway to ramp up ...

You could invest in CRISPR by buying shares of its stock or buying an ETF with exposure to it. Key findings are powered by ChatGPT and based solely off the content from this article. Findings are ...

Short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) increased during the last reporting period, rising from 17.59M to 18.59M. This put 24.68% of the company's publicly available shares short.

CRISPR Therapeutics’ CRSP shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in ...

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Advisors Asset Management Inc. boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.7% in the third quarter, Holdings Channel reports. The firm owned 9,669 shares of the ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...